Combining clinicopathologic staging with the 40-GEP test allows for more accurate prognostic staging of cSCC tumors; this, in turn, improves precision in multidisciplinary treatment recommendations, including the use of ART. The utility of 40-GEP testing has been demonstrated in low-, higher-, and highest-stage cSCC tumors. Additionally, 40-GEP testing has shown greater specificity than current clinicopathologic guidelines in identifying patients at highest risk of nodal or distant metastasis who would most likely benefit from ART, as well as lower risk patients who would benefit less from such therapy. Appropriate use of 40-GEP testing involves a shared decision-making model between the multidisciplinary team and the patient with cSCC, taking into consideration many factors, such as the patient’s risk of metastasis, tumor and nontumor characteristics, and individual preferences.

TissueCypher optimized adherence to clinical guidelines for surveillance and treatment of both BE patients at high and low risk for disease progression. Use of the test can enable physicians to make risk-aligned management decisions, leading to improved patient health outcomes.

Gene Expression Differences Identified in Skin Samples of Mycosis Fungoides, Atopic Dermatitis, and Psoriasis.

Utilizing the 40-GEP test results to guide ART decision-making would result in material savings to Medicare.

In a head-to-head comparison of DecisionDx-Melanoma to AJCCv8 staging for stage I cutaneous melanoma (CM) patients (n=6,883) two cohorts were analyzed using recurrence-free survival and melanoma-specific survival. Results from the study showed that DecisionDx-Melanoma significantly improved patient risk stratification, independent of AJCC staging in patients. In addition, DecisionDx-Melanoma provided greater separation between high-risk (Class 2B) and low-risk (Class 1A) groups than seen between AJCC stage IA and IB.

Utilizing patient data provided through collaboration with the NCI SEER program in patients with Stage I-III CM, 31-GEP class result was a significant independent predistor of both MSS and OS. Patients with 31-GEP results in addition to clinicopathologic factors had improved survival.

Despite definitive surgical treatment, a subset of cutaneous squamous cell carcinomas (cSCC) has an increased risk of regional/distant metastasis making it challenging to identify patients most at risk.1 The 40-gene expression profile (40-GEP) prognostic test improves risk stratification for patients with cSCC with known clinical or histologic risk factors, stratifyingpatients’ risk of metastasis as low (Class 1), higher (Class 2A), or highest (Class 2B) risk.

Using 31-GEP results to guide clinical management and surveillance based on personalized risk of MSS can direct care, improving patient outcomes.